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A troponin T variant linked with pediatric dilated
cardiomyopathy reduces the coupling of thin
filament activation to myosin and calcium binding
Samantha K. Barrick, Lina Greenberg, and Michael J. Greenberg*
Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, St. Louis,
MO 63110

ABSTRACT Dilated cardiomyopathy (DCM) is a significant cause of pediatric heart failure.
Mutations in proteins that regulate cardiac muscle contraction can cause DCM; however, the
mechanisms by which molecular-level mutations contribute to cellular dysfunction are not
well understood. Better understanding of these mechanisms might enable the development
of targeted therapeutics that benefit patient subpopulations with mutations that cause common biophysical defects. We examined the molecular- and cellular-level impacts of a troponin
T variant associated with pediatric-onset DCM, R134G. The R134G variant decreased calcium
sensitivity in an in vitro motility assay. Using stopped-flow and steady-state fluorescence measurements, we determined the molecular mechanism of the altered calcium sensitivity: R134G
decouples calcium binding by troponin from the closed-to-open transition of the thin filament
and decreases the cooperativity of myosin binding to regulated thin filaments. Consistent
with the prediction that these effects would cause reduced force per sarcomere, cardiomyocytes carrying the R134G mutation are hypocontractile. They also show hallmarks of DCM
that lie downstream of the initial insult, including disorganized sarcomeres and cellular hypertrophy. These results reinforce the importance of multiscale studies to fully understand mechanisms underlying human disease and highlight the value of mechanism-based precision
medicine approaches for DCM.
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INTRODUCTION
Familial dilated cardiomyopathy (DCM) is a major cause of heart
failure in both adult and pediatric patients and a significant cause of
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heart transplantation (McNally and Mestroni, 2017; Patel et al.,
2017; Towbin et al., 2017). DCM is characterized by dilation of the
left ventricular chamber and impaired cardiac contractility (Mestroni
et al., 1999). Current treatments developed for adult heart failure
have limited efficacy in the pediatric population, and the 5-y transplant-free survival rate is <50% in children with DCM (Shaddy et al.,
2007; Kantor et al., 2010). Therefore, there is an outstanding clinical
need to develop new therapeutics for pediatric DCM.
Familial DCM is often caused by point mutations in proteins involved in cardiac muscle contraction and mechanosensation, including troponin T (TnT) (McNally and Mestroni, 2017). Troponin T
is part of the troponin complex, which, along with tropomyosin,
regulates the calcium-dependent interactions between force-generating myosin heads and the thin filament. Several mutations in
TnT are associated with severe, early-onset disease (Hershberger
et al., 2009). However, the mechanisms by which mutation-induced
changes in protein interactions at the molecular level affect cardiac
contraction and drive the disease pathogenesis at the cellular level
are not well understood. Furthermore, these disease-driving defects can vary between mutations, even within the same molecule
1677

We purified actin and myosin from porcine ventricles. Porcine
cardiac actin is identical to human cardiac actin, and porcine cardiac
myosin is 97% identical to human cardiac myosin, with indistinguishable biophysical properties (Deacon et al., 2012; Greenberg et al.,
2014; Sung et al., 2015).

R134G decreases thin filament calcium sensitivity

FIGURE 1: Structure of the RTF (PDB ID 6KN7) showing actin (tan),
tropomyosin (blue/cyan), troponin I (green), troponin C (orange),
troponin T (magenta), and R134 of troponin T (yellow). The dashed
line represents an unstructured region of troponin T that is not
resolved in the structure. Adjacent tropomyosin units are shown as
cyan and blue to demonstrate the proximity of R134 to the overlap
region.

(Lynn et al., 2018; Greenberg and Tardiff, 2021; Lavine and Greenberg, 2021). Understanding these mechanisms is a critical step in
developing precision medicine therapeutics that target mutationspecific defects.
To better understand the molecular mechanisms that can drive
DCM disease pathogenesis, we examined the molecular and cellular consequences of a variant in troponin T, R134G, which has been
implicated in pediatric-onset DCM (Hershberger et al., 2008) (Figure
1). Several variants at the R134 position have been implicated in
cardiomyopathy, with clinical significance of individual variants ranging from uncertain to likely pathogenic (Landrum et al., 2018). We
chose to study the likely pathogenic R134G variant, which was
shown to segregate with DCM in a patient cohort (Hershberger
et al., 2009). The small number of patients known to carry this specific variant makes it difficult to definitively determine pathogenicity
from the currently available clinical data (Hershberger et al., 2009;
Landrum et al., 2018). Functional data supporting a plausible pathogenic mechanism would increase the confidence that this variant is
indeed causative for DCM.
Because troponin T plays a critical role in transmitting changes in
calcium binding to troponin C to changes in the tropomyosin position on the thin filament, we tested whether R134G affects calciumbased regulation of interactions between myosin and the thin filament. Our results reveal that the R134G mutation in TnT depresses
both calcium- and myosin-based activation of the thin filament. We
find that R134G decouples calcium binding from the closed-toopen transition of the thin filament, resulting in reduced thin filament activation at saturating calcium concentrations. R134G also
decreases the cooperativity of myosin binding to regulated thin filaments (RTFs). In gene-edited, stem cell–derived cardiomyocytes, we
see reduced contractility that is consistent with the molecular-level
defects, as well as downstream effects on sarcomeric organization
and cell size that are consistent with features of DCM.

RESULTS
To study the effects of the R134G variant at the molecular scale, we
purified recombinant human troponin complex and tropomyosin.
1678 | S. K. Barrick et al.

We used an in vitro motility assay to assess the effect of the R134G
mutation in TnT on thin filament regulation (Figure 2). The speed of
fluorescent RTFs gliding across a myosin-functionalized substrate
was measured as a function of calcium concentration. At low calcium, tropomyosin blocks myosin strong binding to actin and the
RTFs are immobile (stuck). At saturating calcium, the RTFs are fully
activated and the filaments glide at maximal speed. As the calcium
concentration was increased from pCa 9 to pCa 4, the percent of
stuck RTFs decreased from 97 ± 2% to 2 ± 1% for wild type (WT) and
from 97 ± 1% to 9 ± 4% for R134G (Figure 2A). Thus, the stuck filament percent was similar for WT and R134G at pCa 9 (p = 0.91) and
significantly higher for R134G relative to WT at pCa 4 (p = 0.003).
We fitted a Hill equation to the measured filament speed versus
calcium data to obtain the maximal sliding speed (Vmax) and the
calcium concentration at which RTFs glide at half-maximal speed
(pCa50). We found that Vmax was reduced for R134G RTFs compared
with WT (Vmax [WT] = 0.23 ± 0.01 μm/s, Vmax [R134G] = 0.15 ± 0.01
μm/s; p < 0.001) (Figure 2B). We did not detect a statistically significant change in the Hill coefficient (nH [WT] = 1.5 ± 0.5, nH [R134G]
= 1.8 ± 0.6; p = 0.66). We plotted the normalized gliding speeds as
a function of calcium concentration to illustrate the decrease in calcium sensitivity caused by the R134G variant (Figure 2C). The pCa50
for RTFs regulated by R134G troponin was significantly lower than
that for WT troponin (pCa50 [WT] = 6.0 ± 0.1, pCa50 [R134G] = 5.3 ±
0.1; p < 0.001). This decrease in the calcium sensitivity of RTF motility indicates that more calcium is needed for the variant to achieve
the same level of activation as the WT. These results suggest that
cardiomyocytes expressing the R134G variant might demonstrate
decreased force per sarcomere during a calcium transient, which
would be consistent with the impaired systolic function observed in
DCM patients carrying the R134G mutation (Hershberger et al.,
2008).
Muscle activation requires both calcium- and myosin-dependent
activation of the thin filament (Houmeida et al., 2010). The decreased calcium sensitivity observed in the in vitro motility assay
could be caused by mutation-induced changes in 1) cross-bridge
dissociation kinetics, 2) calcium binding affinity to troponin C, and/
or 3) equilibrium positioning or cooperativity of tropomyosin movement along the thin filament. We measured each of these properties
to determine which are responsible for the shift in calcium sensitivity
caused by R134G.

R134G does not affect actomyosin dissociation kinetics
Thin filament activation depends on myosin binding to the thin filament, which locks tropomyosin in a position that allows cooperative
binding of additional nearby myosin molecules. A mutation-induced
increase in the rate of myosin cross-bridge detachment would decrease thin filament activation by decreasing the time myosin
spends in the activating, strongly bound state. The rate of crossbridge detachment in the absence of load is limited by the rate of
ADP release from actomyosin (Bárány, 1967; Siemankowski et al.,
1985). To test whether the decreased calcium sensitivity in the motility assay was due to changes in the cross-bridge detachment rate,
we used a stopped-flow transient kinetic assay to measure the rate
of ADP release from actomyosin S1 (Figure 3). We found that
Molecular Biology of the Cell

FIGURE 3: Stopped-flow kinetic traces measuring the ADP release
rate from actomyosin after rapid mixing of ATP with pyrene-labeled
RTFs bound to myosin and ADP. The pyrene fluorescence increases as
myosin S1 dissociates from actin after release of ADP. Traces are the
average of three (WT) or two (R134G) independent experiments, each
the average of five technical replicates. The WT trace (k = 76.7 ±
0.2 s–1) is partially obscured by the R134G trace (k = 78.8 ± 0.2 s–1) due
to the similar rates. R134G does not alter the rate of ADP release
from actomyosin S1 (p = 0.35).

the R134G variant had no effect on the ADP release rate constant
(k [WT] = 76.7 ± 0.2 s–1, k [R134G] = 78.8 ± 0.2 s–1; p = 0.35). This is
consistent with previous measurements of ADP release from cardiac
actomyosin S1 (Deacon et al., 2012; Greenberg et al., 2014;
Clippinger et al., 2019, 2021). Thus, altered kinetics of actomyosin
dissociation are not responsible for the decreased calcium sensitivity observed in the in vitro motility assay (Figure 2).

R134G increases the calcium sensitivity of troponin C
The decreased calcium sensitivity observed in the motility assay
could also be caused by a reduction in the calcium binding affinity of troponin through an allosteric effect of the R134G mutation
in TnT on troponin C (TnC). To test this possibility, we measured
the calcium binding affinity of RTFs containing TnC site–specifically labeled with IAANS (2-(4′-(iodoacetamido)anilino)napthalene-6-sulfonic acid), an environmentally sensitive fluorophore.
The response of IAANS fluorescence to calcium-dependent
changes in TnC conformation provides a convenient method for
monitoring calcium binding to TnC (Davis et al., 2007; Tikunova
et al., 2010; Liu et al., 2012). Unexpectedly, we found that R134G
TnT increased calcium binding to TnC within RTFs (pCa50 [WT] =
6.29 ± 0.07, pCa50 [R134G] = 6.6 ± 0.1; p < 0.001) (Figure 4). This
increased calcium binding sensitivity for R134G troponin cannot
explain the decrease in calcium sensitivity observed in the motility assay (Figure 2).
FIGURE 2: (A) Percent stuck filaments in an in vitro motility assay at
pCa 9 (97 ± 2% for WT, 97 ± 1% for R134G; p = 0.91) and pCa 4 (2 ±
1% for WT, 9 ± 4% for R134G; p = 0.003). Asterisk indicates a
statistically significant difference in the percent stuck filaments at pCa
4. Raw (B) and normalized (C) RTF gliding speed as a function of
calcium concentration in the in vitro motility assay. Curves are fits to a
Hill equation. Error bars represent SEM of 150 tracked RTFs from
three independent experimental days. R134G (Vmax = 0.15 ± 0.1 μm/s)
Volume 32 August 19, 2021

results in a decrease in the maximum gliding speed relative to WT
(Vmax = 0.23 ± 0.1 μm/s; p < 0.001). Normalized RTF gliding speed is
shown to more clearly illustrate the decrease in calcium sensitivity
caused by the R134G variant (pCa50 [R134G] = 5.3 ± 0.1, pCa50 [WT] =
6.0 ± 0.1; p < 0.001). Note that data collected at pCa 6.75, 7, 8, and 9
are obscured by the fit line.

DCM variant uncouples RTF activation
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FIGURE 4: Calcium binding affinity of TnC within RTFs as a function
of calcium concentration. Normalized calcium binding was determined
from steady-state fluorescence of IAANS-labeled TnC. Data were
fitted with the Hill equation. Error bars represent SD of five replicates.
TnC within RTFs containing R134G TnT (pCa50 = 6.6 ± 0.1) showed
increased calcium sensitivity compared with RTFs containing WT TnT
(pCa50 = 6.29 ± 0.07; p < 0.001).

R134G decouples the closed-to-open transition from
calcium binding and reduces the cooperativity of myosin
binding to RTFs
Tropomyosin can lie in three distinct positions along the thin filament: blocked, closed, and open (McKillop and Geeves, 1993; Vibert et al., 1997). The distribution of tropomyosin among these three
positions is affected by both calcium binding to troponin C and
myosin binding to the thin filament (Figure 5A). The blocked state,
in which tropomyosin blocks the myosin binding site on the thin filament, is significantly occupied only at low calcium concentrations.
Myosin strong binding and subsequent force generation occur only
in the open state of the thin filament. The fraction of force-generating thin filament regulatory units will thus depend on the equilibrium constants that define the transitions between these states. The
process of thin filament activation is cooperative due to coupling
between thin filament regulatory units via tropomyosin end-to-end
bonds (Greene and Eisenberg, 1980; Moore et al., 2016). The
R134G mutation could decrease the calcium sensitivity of RTFs by
shifting the equilibrium positioning of tropomyosin and/or by decreasing the cooperativity of activation, resulting in the higher calcium concentrations required to activate the RTF and generate
force. We examined the effect of the R134G variant on tropomyosin
positioning using fluorescence-based assays of regulated actomyosin binding to determine the equilibrium constants for the blockedto-closed (KB) and closed-to-open (KT) transitions of the thin filament (Figure 5).
To determine KB, we measured the calcium-dependent binding
of myosin subfragment-1 (myosin S1) to pyrene-labeled RTFs in a
stopped-flow kinetic assay (McKillop and Geeves, 1993; Barrick
et al., 2019). Myosin strong binding quenches the fluorescence of
pyrene-labeled actin, resulting in a decrease in fluorescence. KB, the
equilibrium constant for the blocked-to-closed transition, can be
determined from the relative rates of S1 binding at pCa 9 (low calcium) and pCa 4 (saturating calcium) (see Materials and Methods for
details). The calcium-dependent rates of binding to the RTF were
similar for WT and R134G (Figure 5, B and C), and the calculated KB
1680 | S. K. Barrick et al.

values were indistinguishable (KB [WT] = 0.3 ± 0.2, KB [R134G] = 0.3
± 0.1; p = 0.76). Thus, R134G does not affect the equilibrium constant between the blocked and closed states.
To measure the equilibrium constant for the closed-to-open transition of the thin filament, KT, we performed fluorescence titrations
of steady-state myosin S1 binding to pyrene-labeled RTFs (McKillop
and Geeves, 1993; Barrick et al., 2019) (Figure 5, D and E). By fitting
the titration data with an equation relating the fractional change in
pyrene fluorescence to the extent of S1 binding (see Materials and
Methods), we obtained estimates for the values of KT, as well as KW,
the equilibrium constant for myosin weak binding to actin, and nH,
the apparent size of the cooperative unit, as previously described in
detail (Barrick et al., 2019). The values of these parameter estimates
are summarized in Figure 5F.
For RTFs regulated by WT troponin, the value of KT increased
with calcium concentration, as previously observed by us and others
(McKillop and Geeves, 1993; Barrick et al., 2019; Clippinger et al.,
2019). In contrast, the KT value did not depend on calcium for RTFs
regulated by R134G troponin (Figure 5F). This can be seen qualitatively from the plots of fractional binding as a function of myosin
concentration. In contrast to the WT (Figure 5D), the fractional bindings to RTFs containing R134G troponin (Figure 5E) are very similar
at pCa 6.25 and 4. This suggests that the R134G mutation decouples
the thin filament closed-to-open transition from calcium binding to
TnC. Compared to WT, the KT value for R134G was higher at low
calcium (pCa 9) and lower at saturating calcium (pCa 4). At pCa 9,
the level of thin filament activation is low despite the increased value
of KT because most thin filaments adopt the blocked state. At pCa 4,
tropomyosin is less likely to adopt the open position for R134G compared with WT. This predicts a mutation-induced reduction in population of the myosin-bound states, consistent with the shift in calcium
sensitivity and decrease in Vmax seen in the motility assay.
The R134G mutation resulted in a significant decrease in the Hill
coefficient nH (Figure 5F), which can be interpreted as the apparent
size of the cooperative unit (McKillop and Geeves, 1993; Mijailovich
et al., 2012). Higher values of nH suggest longer-range cooperativity.
For WT troponin, the best-fit value was nH = 6 (–1/+1), which is similar to previously reported values (Maytum et al., 1999; Clippinger
et al., 2019). R134G thin filaments showed reduced cooperativity
(nH = 3.2 [–0.2/+0.3]; p = 0.002), indicating that the R134G mutation
limits the propagation of thin filament activation. This reduction in
cooperativity would be expected to reduce activation, consistent
with the shift in calcium sensitivity seen in the motility assay.
There was also a small but statistically significant increase in KW
associated with the R134G variant (Figure 5F). This corresponds to a
shift in the equilibrium toward weakly bound rather than dissociated
myosin; however, it is unlikely that an increase of this magnitude
would have biological significance. Regardless, an increase in KW
predicts slightly increased myosin weak binding, so this change cannot explain the decreased calcium sensitivity caused by the R134G
mutation in the in vitro motility assay (Figure 2).
Together, these molecular-level measurements demonstrate that
the mutation-induced decrease in calcium sensitivity observed in
the in vitro motility assay is primarily caused by reduced coupling of
calcium binding to changes in tropomyosin positioning, resulting in
reduced occupancy of the open state in the presence of calcium,
and/or a decrease in the cooperativity of myosin binding to RTFs.

R134G results in increased cell area and sarcomeric
disorganization in hiPSC-CMs
To examine the effect of the R134G mutation in a cellular context,
we used CRISPR/Cas9 gene editing to generate human induced
Molecular Biology of the Cell

at least 30 d before any assays were performed, as previously described (Clippinger
et al., 2019). hiPSC-CMs showed spontaneous beating starting at days 7–10 after the
initiation of the differentiation.
R134G and WT hiPSC-CMs were each
micropatterned onto glass coated with
rectangular patterns of extracellular matrix,
fixed, stained for troponin I and α-actinin
to visualize the sarcomeres, and imaged
using confocal microscopy (Figure 6, A and
B). We observed larger cell areas for the
R134G hiPSC-CMs (1800 ± 200 μm2) compared with WT hiPSC-CMs (1000 ± 50 μm2;
p = 0.002) (Figure 6; Table 1), as we previously observed for a different DCM-causing mutation in TnT (Clippinger et al.,
2019). We also observed a decreased aspect ratio for the R134G hiPSC-CMs relative to WT (Figure 6; Table 1). Moreover,
the sarcomeres in the micropatterned WT
hiPSC-CMs are well organized and tend to
align along the long axis of the cell, as previously described (Clippinger et al., 2019).
In contrast, the sarcomeres in the R134G
hiPSC-CMs appear more disorganized and
fail to align along a single axis. We frequently observe sarcomeres that appear
more wavy than linear (see Figure 6B). The
sarcomere lengths of fixed cells for the mutant were longer than those for the WT
cells on glass, but this difference disappeared on 10 kPa hydrogels. Taken together, these results demonstrate mutation-induced changes in cell shape and
sarcomeric organization.

R134G decreases the force generated
during cardiomyocyte contraction
To test whether R134G affects contractility,
as predicted from the molecular mechanism, we performed traction force microscopy on hiPSC-CMs to measure cardiomyoFIGURE 5: Effects of R134G on tropomyosin positioning along the thin filament. (A) Schematic
cyte contraction. Spontaneously beating
of the three-state model of thin filament regulation. The equilibrium constants KB and KT
hiPSC-CMs were seeded onto 10 kPa hydrodescribe the blocked-to-closed and closed-to-open transitions of the thin filament, respectively.
gels micropatterned with extracellular maKW and KS describe weak and strong myosin binding, respectively. (B, C) Measurement of KB.
trix in rectangles with a 7:1 aspect ratio. This
Stopped-flow kinetic traces of myosin S1 binding to RTFs containing pyrene-actin and WT (B) or
patterning onto hydrogels of physiological
R134G (C) troponin T. Traces are the average of 10 independent experiments, each the average
stiffness promotes sarcomeric alignment
of at least three technical replicates. S1 binding quenches the pyrene fluorescence at a higher
and cellular maturation (Ribeiro et al., 2015).
rate at high calcium (pCa 4, green) than at low calcium (pCa 9, magenta) in each case. The value
The displacement of fluorescent microof KB was determined using Eq. 1 (Materials and Methods). (D, E) Measurement of KT and KW.
Steady-state titrations of RTFs with S1 for WT (D) and R134G (E) at three calcium concentrations: beads embedded in the hydrogels was
saturating (pCa 4, green), intermediate (pCa 6.25, orange), and low (pCa 9, magenta). Curves
used to monitor cardiomyocyte beating
are fits of Eq. 2 (Materials and Methods) to the data. Error bars represent the SD of six technical (Figure 7A). The force of contraction for
replicates collected on six independent experimental days. (F) Table of parameter values
each cell was calculated using a MATLAB
determined for WT and R134G. KB was determined from the stopped-flow measurements and is program developed by the Pruitt laboratory
given as the average ± SD of 10 replicates. All other parameters were determined from the
(Ribeiro et al., 2017). The contractile force
steady-state titrations and are given as best-fit values with 95% confidence intervals. Asterisks
exerted by R134G cardiomyocytes (0.17
indicate statistical significance at the 95% confidence interval.
[–0.03/+0.04] μN) was lower than the WT
pluripotent stem cell–derived cardiomyocytes (hiPSC-CMs) homoforce (0.27 [–0.03/+0.03] μN; p = 0.002) (Figure 7; Table 1). The
zygous for the R134G mutation in TnT. hiPSCs were differentiated to
R134G variant also reduced the contractile power exerted by the
cardiomyocytes by temporal modulation of Wnt signaling and aged
cells, as well as the contraction and relaxation velocities, relative to
Volume 32 August 19, 2021
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FIGURE 6: Representative immunofluorescence images of
sarcomeres in hiPSC-CMs on a rectangular pattern on glass. Troponin
I is red, and α-actinin is green. Images are z-projections. (A) WT
hiPSC-CM. (B) R134G hiPSC-CM. R134G hiPSC-CMs exhibit
sarcomeric disorganization and increased cell area. (C) Quantification
of areas, aspect ratios, and sarcomere lengths from immuno
fluorescence images of WT (n = 120) and R134G (n = 39) hiPSC-CMs
on glass and sarcomere lengths of WT (n = 33) and R134G (n = 31)
hiPSC-CMs on hydrogel. Data are plotted as cumulative distributions,
and parameter values are given in Table 1. R134G hiPSC-CMs had a
larger cell area (p = 0.002) and a smaller aspect ratio (p = 0.028) than
WT hiPSC-CMs. R134G hiPSC-CMs had longer sarcomere lengths
than WT hiPSC-CMs on glass (p = 0.004) but not on hydrogel (p =
0.342).

WT (Figure 7; Table 1). These effects are consistent with our proposed molecular mechanism as well as the diminished force production observed for other known pathogenic DCM mutations (Sun
et al., 2012; Clippinger et al., 2019).

DISCUSSION
Evidence for the pathogenicity of R134G
One challenge for the field has been connecting genotype and patient phenotype, in part because many variants occur in a small
number of patients, with insufficient numbers to draw firm conclusions about the pathogenicity of a given variant. Mechanistic studies
1682 | S. K. Barrick et al.

FIGURE 7: (A) Representative force transients of beating hiPSC-CMs
measured using traction force microscopy. R134G hiPSC-CMs show
reduced contractility compared with WT. (B) Quantification of force,
power, and contraction and relaxation velocities measured using
traction force microscopy. Data are plotted as cumulative
distributions, and parameter values are given in Table 1. R134G (n =
97 cells) decreased the traction force (p = 0.002), power (p = 0.018),
and contraction (p = 0.006) and relaxation (p = 0.012) velocities
relative to WT (n = 158 cells).

can inform whether a given variant is likely pathogenic or not; however, these mechanistic studies are currently not a substitute for
clinical genetics studies.
Our molecular studies of the R134G variant revealed decreased
calcium sensitivity for activation, similar to those observed for troponin T mutations known to be pathogenic for DCM (Hershberger
et al., 2009; Gangadharan et al., 2017; Clippinger et al., 2019). Previous studies of R134G force development in porcine skinned cardiac muscle fibers or in vitro actomyosin ATPase activity each detected small decreases in calcium sensitivity that did not reach
statistical significance (Hershberger et al., 2009; Gangadharan et al.,
2017). Here, we report a statistically significant decrease in the calcium sensitivity of sliding speed in our in vitro motility measurements. Moreover, we generated a mutant stem cell line carrying the
R134G variant that was isogenic to the parent WT line, except for
the mutation. These cells showed reduced contractile function, sarcomeric disarray, and changes in cell size that are consistent with
Molecular Biology of the Cell

Parameter

WT

R134G

p

Traction force (μN)

0.27 (–0.03/+0.03)

0.17 (–0.03/+0.04)

0.002

Power (pW)

0.10 (–0.02/+0.02)

0.06 (–0.02/+0.03)

0.018

Contraction velocity (μm/s)

0.33 (–0.04/+0.04)

0.22 (–0.04/+0.05)

0.006

Relaxation velocity (μm/s)

0.24 (–0.03/+0.03)

0.18 (–0.03/+0.04)

0.012

1000 (–50/+50)

2

Cell area (μm )

1800 (–200/+200)

0.002

6.7 (–0.3/+0.2)

6.1 (–0.5/+0.5)

0.028

Sarcomere length (μm)

1.65 (–0.03/+0.04)

1.77 (–0.05/+0.06)

0.004

Sarcomere length on hydrogel (μm)

1.71 (–0.06/+0.06)

1.75 (–0.06/+0.06)

0.342

Aspect ratio

Average traction force, contraction power, and contraction and relaxation velocities of WT (n = 158) and R134G (n = 97) hiPSC-CMs were measured using traction
force microscopy (see Figure 7). Average cell areas, aspect ratios, and sarcomere lengths were determined from immunofluorescence images of WT (n = 120) and
R134G (n = 39) hiPSC-CMs on rectangular patterns on glass (see Figure 6). Sarcomere lengths were also measured for WT (n = 33) and R134G (n = 31) hiPSC-CMs on
rectangular patterns on hydrogel. Reported uncertainties are 95% confidence intervals determined by bootstrapping.

TABLE 1: Comparison of hiPSC-CMs expressing WT or R134G troponin T.

studies of known pathogenic DCM mutations in hiPSC-CMs (Sun
et al., 2012; Hinson et al., 2015; Clippinger et al., 2019; Lee et al.,
2019). Cellular hypocontractility is also consistent with the systolic
dysfunction associated with DCM (Mestroni et al., 1999; Davis et al.,
2016). Therefore, the data presented here are consistent with the
classification of R134G as a pathogenic variant.

Uncoupling of calcium binding and tropomyosin positioning
The R134G variant decreased the calcium sensitivity of RTF motility
(Figure 2) despite the increased affinity of TnC for calcium within
RTFs containing R134G TnT, relative to WT (Figure 4). The effect of
a mutation in TnT on calcium binding by TnC is consistent with previous work showing that two mutations at the R92 position of troponin T differentially altered calcium binding through a complex network of allosteric interactions (Williams et al., 2016). Our data
suggest that the R134G mutation alters allosteric communication
among thin filament proteins such that the coupling between tropomyosin positioning and calcium binding to troponin C is reduced.
This is consistent with a study showing that the nearby hypertrophic
cardiomyopathy mutation ΔE160 can affect the coupling between
the troponin core complex and the tropomyosin overlap region
(Abdullah et al., 2019).
The notion that R134G affects the coupling between calcium
binding and tropomyosin movement is also supported by our measurements of tropomyosin positioning (Figure 5). The activation of
thin filaments regulated by WT troponin contains two calcium-dependent transitions, namely between the blocked and closed states
and between the closed and open states (McKillop and Geeves,
1993). R134G abolishes the calcium dependence of KT, the equilibrium constant between the closed and open states of the thin filament, without affecting KB (Figure 5). Thus, the R134G mutation
uncouples the closed-to-open transition of the thin filament from
calcium binding to troponin.
The uncoupling of tropomyosin positioning from calcium binding results in different effects of R134G on thin filament activation at
different calcium concentrations. At low calcium (pCa 9), the larger
value of KT for R134G signifies increased thin filament activation
relative to WT; however, the overall level of activation for both WT
and R134G RTFs is low because both KB and KT are small (≤0.3),
indicating that most of the regulatory units are in the blocked state.
Consistent with this observation, the fraction of stuck filaments in
the in vitro motility assay at pCa 9 is the same for both the WT and
mutant troponin. Therefore, the increase in KT at pCa 9 is not suffiVolume 32 August 19, 2021

cient to increase the motility of RTFs containing R134G troponin
(Figure 2). At pCa 4, the value of KT is small for R134G relative to
WT, which demonstrates reduced activation at high calcium concentrations and could account for the decrease in Vmax in the in vitro
motility assay. A shift in equilibrium tropomyosin positioning toward
the closed state at saturating calcium levels is also consistent with
reduced force generation, as has been described for a double mutation in troponin C thought to cause dilated cardiomyopathy (Dweck
et al., 2010).
A mutation-induced reduction in thin filament activation at saturating calcium concentrations may also help explain the shift in calcium sensitivity of RTF motility (Figure 2). The motility rate in the
absence of regulatory proteins is frequently assumed to be limited
by the rate of actomyosin dissociation (Huxley, 1990); however, we
do not observe a change in the rate of ADP release with the mutant
protein (Figure 3). Therefore, it is likely that the mutant is affecting
attachment kinetics, which is reasonable because the transition to
strong binding is regulated by troponin and tropomyosin. Therefore, the reduced maximal speed in the motility assay is consistent
with the reduced actin-activated ATPase rate measured with R134GRTFs at fully activating calcium concentrations (Gangadharan et al.,
2017).
Although pCa 9 and 4 are extreme values relative to the typical
range of calcium concentrations in a physiological calcium transient,
pCa 6–7 (Bers, 2002), we believe that measurements at pCa 9 and 4
provide meaningful insight into relaxed and fully activated conditions, respectively. We did not detect a significant difference in the
value of KT at pCa 6.25, but we did observe decreased motility at
intermediate calcium concentrations for R134G relative to WT. This
discrepancy could be due to differences in the sensitivity of the respective assays and/or slight differences in the calcium-dependent
behavior measured under different conditions (i.e., different buffers,
protein concentrations, etc.). Alternatively, these results may suggest that the observed decrease in thin filament cooperativity is the
primary physiological effect of the mutation.

Reduced coupling of myosin binding to thin filament
activation
Our measurements also revealed a decrease in the cooperativity of
myosin binding to thin filaments regulated by R134G TnT, relative to
WT. This is important because full thin filament activation depends
on both calcium and myosin binding (Houmeida et al., 2010). This
finding is qualitatively consistent with the decreased Hill coefficient
DCM variant uncouples RTF activation
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of actomyosin ATPase activity observed for R134G TnT relative to
WT (Gangadharan et al., 2017). While we did not observe a statistically significant change in the Hill coefficient in the motility assay,
this could be due to the large uncertainty in determining this value.
Moreover, it should be noted that the Hill coefficients measured for
motility, ATPase activity, and myosin binding to RTFs in equilibrium
titrations are not necessarily equivalent. That being said, decreased
cooperativity of thin filament activation would result in decreased
accessibility of myosin binding sites along the thin filament. This
contributes to the decreased calcium sensitivity in the in vitro motility assay because a decrease in myosin-induced activation should
result in a requirement for additional calcium-based activation to
achieve the same level of thin filament activation. Decreased accessibility of myosin binding sites along the thin filament is also predicted to reduce force generation in cardiomyocytes.

Potential structural mechanism of reduced cooperativity
We can gain insights into the potential structural mechanism of the
reduced coupling of thin filament activation to myosin binding by
examining recent crystal and cryogenic electron microscopy structures (Yamada et al., 2020; Risi et al., 2021). The core of the troponin
complex consists of troponin C, most of troponin I, and the C-terminal region of troponin T (Takeda et al., 2003). The N-terminal 2/3 of
troponin T stretches from this core complex in an elongated conformation that interacts with tropomyosin filaments on both sides of
the thin filament. This extended structure thus couples the core
complex to tropomyosin. R134 is located within the region of TnT
that binds the tropomyosin overlap region (Jin and Chong, 2010;
Gangadharan et al., 2017), near the end of the linker between the
core complex and the tropomyosin on the other side of the thin filament (see Figure 1). In vitro measurements of tropomyosin-TnT
binding affinity revealed that the R134G variant, along with several
other DCM-causing mutations within the TnT N-terminal domain,
increases the affinity of TnT for tropomyosin (Gangadharan et al.,
2017). This result is consistent with the notion that altered interactions between TnT and tropomyosin can be important for cardiomyopathy pathogenesis (Palm et al., 2001; Manning et al., 2012;
Gangadharan et al., 2017; McConnell et al., 2017; Madan et al.,
2020). Additionally, it has been shown that hypertrophic cardiomyopathy-associated mutations impair the ability of a TnT fragment
(TnT70-170) to increase the affinity of tropomyosin for actin and to
stabilize the tropomyosin overlap region, where tropomyosin molecules interact in a head-to-tail manner (Palm et al., 2001). Taken together, these observations suggest that mutation-induced alterations in TnT-tropomyosin contacts could affect the head-to-tail
interactions within the tropomyosin polymer as well as the actintropomyosin binding interface. We propose that these changes
could contribute to the decrease in cooperativity of regulated actomyosin binding induced by the R134G mutation. Further structural
and computational studies are needed to shed light on this potential mechanism.

Cellular consequences of the R134G variant
Our molecular studies suggest that the initial molecular insult driving disease pathogenesis is altered thin filament regulation that decreases thin filament activation, which is consistent with the decreased sarcomeric contractility observed in our stem cell–derived
cardiomyocyte model of R134G (Figure 7; Table 1). This molecular
and cellular hypocontractility has also been observed with other
DCM-causing mutations (Sun et al., 2012; Davis et al., 2016; Yuan
et al., 2018; Clippinger et al., 2019). We also observed downstream
effects of the initial molecular insult in hiPSC-CMs engineered to
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express R134G TnT; namely, sarcomeric disorganization and increased cell area (Figure 6). These observations suggest that the
initial molecular insult of altered mechanics can drive downstream
alterations in cellular function beyond contractility. The exact mediators of these cellular changes are unknown; however, they likely involve the activation of mechanobiological signaling pathways.

Implications for precision medicine
Our study adds to the growing body of evidence that even within
the same gene, not all mutations will have the same underlying
molecular mechanism (Harada and Potter, 2004; Schmitt et al., 2006;
Williams et al., 2016; Barrick et al., 2019; Clippinger et al., 2019,
2021; Ezekian et al., 2020). For example, a previous study of another
DCM-causing mutation in troponin T, ΔK210, also showed decreased
calcium sensitivity of RTF motility and increased cell size in hiPSCCMs, in addition to hypocontractility and sarcomeric disorganization
(Clippinger et al., 2019). However, the molecular-level effects of
R134G are distinct from those of ΔK210, which uniformly decreased
thin filament activation (KT) without altering cooperativity (nH) in
steady-state measurements of regulated actomyosin binding.
Our observation of the increased calcium binding affinity of
R134G troponin was unexpected because increased calcium binding to the troponin complex has been associated with mutations
causing hypertrophic cardiomyopathy and molecular hypercontractility, not dilated cardiomyopathy (Robinson et al., 2007, 2018).
However, as we demonstrate here, measurement of calcium binding
affinity alone is insufficient to determine the consequences on thin
filament regulation and contractility. The sarcomere is a complicated
macromolecular complex, and mutation-induced changes in protein
structure and function can lead to alterations in its interactions with
multiple binding partners. As such, our results reiterate the complexity of disease pathogenesis and the value of multiscale characterization of disease-causing mutations. Although the molecularlevel results do not uniformly predict molecular hypocontractility,
the cellular phenotype conferred by the R134G variant is wholly
consistent with cellular hypocontractility and DCM.
These results have important implications for the design of precision medicine therapeutics. Multiple molecular insults can lead to
DCM. This heterogeneity has made it difficult to design therapeutics
for DCM that work for all patients. We propose binning patient mutations based on the underlying molecular mechanism and designing precision therapeutics for these patient subpopulations based
on reversing the underlying molecular mechanism (Greenberg and
Tardiff, 2021; Lavine and Greenberg, 2021). Although the R134G
variant increases calcium binding to the thin filament, a calcium-desensitizing drug that renormalizes this calcium binding would likely
exacerbate the disease phenotype rather than repair it. Conversely,
a drug designed to treat DCM by increasing the affinity of TnC for
calcium would not be likely to improve the condition of a patient
carrying the R134G mutation, but such a drug might be effective for
DCM-causing mutations shown to decrease the calcium affinity of
TnC within RTFs (Robinson et al., 2007; Liu et al., 2012). We speculate that omecamtiv mecarbil (Malik et al., 2011), which increases
thin filament activation by increasing myosin binding (Woody et al.,
2018), would be better tailored for repairing the molecular insult of
R134G. In summary, our results emphasize the value of mechanismbased precision medicine in treating genetic cardiomyopathies.

Limitations of our study
It is important to note that our study has several limitations in the
extrapolation to DCM more generally. Stem cell–derived cardiomyocytes are developmentally immature, and therefore, give windows
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into the early disease pathogenesis, rather than late-stage disease
(Musunuru et al., 2018). Although our results are consistent between
the molecular and cellular levels, the contractility in hiPSC-CMs can
also be modified by factors beyond those considered here, including adaptive changes in calcium handling, protein isoform switching, and posttranslational modifications of proteins. These cellular
changes will vary over the course of the disease progression. In addition, we used homozygous isogenic lines to facilitate the comparison between the molecular and cellular levels, whereas patients are
usually heterozygous. That being said, homozygous cells carrying
DCM mutations can recapitulate many disease features seen with
heterozygous lines (Hinson et al., 2015). Finally, it should be noted
that although we see changes consistent with a DCM phenotype
with R134G at both the molecular and cellular levels, definitive determination of pathogenicity in patients requires further genetic and
clinical studies.

Conclusions
In summary, we provide functional data supporting the classification
of the R134G mutation in TnT as a likely pathogenic mutation. Specifically, R134G induces a statistically significant decrease in calcium
sensitivity of regulated actomyosin motility, which results in decreased cardiomyocyte force generation. Our data suggest that decreased cooperativity of regulated actomyosin binding and uncoupling of calcium binding from tropomyosin movement are the
primary drivers of R134G pathogenicity, which is, to our knowledge,
a novel pathogenic mechanism. These results emphasize the value of
a precision medicine approach to treating cardiomyopathies, wherein
knowledge of mutation-specific effects on cardiac function are used
to more effectively treat patients diagnosed with genetic DCM.

MATERIALS AND METHODS
Request a protocol through Bio-protocol.

Protein expression and purification
Cardiac ventricular myosin and actin were each prepared from cryoground porcine ventricles (Pelfreez) as previously described (Greenberg et al., 2014). Myosin S1 was isolated from full-length myosin by
digestion with chymotrypsin (Margossian and Lowey, 1982; Eads
et al., 1984), and its purity was assessed using SDS–PAGE. Cardiac
actin was labeled with N-(1-pyrenyl)iodoacetamide (pyrene) as described in Pollard (1984). Protein concentrations were measured
spectroscopically for actin (290 nm), pyrene-actin (290 and 344 nm),
and myosin S1 (280 and 320 nm). The concentration of full-length
myosin was measured using a Bradford assay.
Recombinant human tropomyosin (NP_001018005.1) was expressed in BL21-CodonPlus cells (Agilent) and purified using established protocols (Hitchcock-DeGregori and Heald, 1987), as we
have done previously (Barrick et al., 2019; Clippinger et al., 2019).
The concentration of tropomyosin was determined by measuring
the absorbance at 280 nm. To remove aggregates before each experiment, tropomyosin was reduced by the addition of 50 mM dithiothreitol (DTT), heated at 56°C for 5 min, and allowed to cool to
room temperature before centrifuging for 30 min at 436,000 × g at
4°C in an Optima MAX-TL Ultracentrifuge (Beckman Coulter)
equipped with a TLA 120.2 rotor (Beckman Coulter).
Human recombinant troponins I (NP_000354.4), C (NP_003271.1),
and T (NP_001001430.1) were expressed in BL21-CodonPlus cells,
complexed, and purified using established protocols (Kozaili et al.,
2010), with the modification that the complexed protein was purified using a MonoQ column (GE Healthcare). The concentration of
the troponin complex was measured spectroscopically using a BradVolume 32 August 19, 2021

ford assay (Coomassie Plus Assay kit; Thermo Scientific). The R134G
mutation was introduced into troponin T using the QuikChange
Site-Directed Mutagenesis Kit (Agilent) and verified by sequencing
(GENEWIZ). R134G troponin T was expressed, complexed with troponins I and C, and purified using the same procedure as the WT
protein. All assays were conducted using two independent preparations of the R134G troponin T variant.

In vitro motility assay
Experiments were conducted as previously described (Clippinger
et al., 2019). Unless otherwise specified, reagents were diluted in
KMg25 buffer (25 mM KCl, 2 mM ethylene glycol-bis(β-aminoethyl
ether)-N,N,N′,N′-tetraacetic acid (EGTA), 60 mM MOPS, pH 7.0,
4 mM free MgCl2, 1 mM DTT). Phalloidin-stabilized F-actin (unlabeled
or rhodamine labeled) was prepared by incubating G-actin (23.8 or
2 µM) with 26.2 µM phalloidin or 3.75 µM rhodamine-phalloidin for
at least 30 min at room temperature. Before measurements, nonfunctional myosin “dead heads” were removed by centrifuging myosin solution (2 µM myosin, 4 µM phalloidin-stabilized F-actin, 1 mM
ATP in high-salt buffer [KMg25 with 300 mM KCl]) for 30 min at
436,000 × g at 4°C in an Optima MAX-TL Ultracentrifuge (Beckman
Coulter) equipped with a TLA 120.2 rotor (Beckman Coulter). The
concentration of myosin in the supernatant was measured using a
Bradford reagent (Coomassie Plus Assay kit; Thermo Scientific) and
diluted to the desired concentration in high-salt buffer. Coverslips
(VWR) were cleaned with compressed air and coated with 1% nitrocellulose in amyl acetates (both from Electron Microscopy Sciences)
using the side of a pipette tip to spread the nitrocellulose across the
coverslip. Nitrocellulose-coated coverslips were allowed to dry in a
covered container for at least 30 min before the flow cells were
assembled.
Flow cells were created by fixing a nitrocellulose-coated coverslip to an uncoated coverslip using double-sided tape and vacuum
grease. For each measurement, a flow cell was loaded by pipetting
50 µl (∼1 volume) of each of the following reagents into the channel:
myosin (0.2–0.4 µM, 1 min); bovine serum albumin (1 mg/ml, 2 ×
1 min); phalloidin-stabilized F-actin (1 µM, 2 × 1 min); Mg·ATP (5 mM
each ATP and MgCl2, 100 µl wash); KMg25 (200 µl wash); rhodamine-labeled phalloidin-stabilized F-actin (40 nM, 1 min); tropomyosin and troponin (0.2 µM each, 1 min); activation buffer (KMg25
supplemented with 5 mM MgCl2, 10 mM DTT, 5 mM ATP, 0.5%
methylcellulose, 0.2 µM each tropomyosin and troponin, 2.5 mg/ml
glucose, 5 U/ml glucose oxidase [Sigma], 11 µg/ml catalase [Sigma],
and CaCl2 to the desired calcium concentration). The added
calcium required to achieve each desired final free calcium concentration was determined using MaxChelator (Bers et al., 2010).
Flow cells were imaged using an IX70 fluorescence microscope
(Olympus) controlled by Ocular software (QImaging). Rhodamine
fluorescence was excited through a 532 nm filter, and movies were
captured by a Retiga R1 charge-coupled device camera (QImaging)
with an exposure time of 400 ms. The frame rate and total number
of frames were empirically set for each calcium concentration: typically 20 frames at 3-s intervals for high calcium and 10 frames at 10-s
intervals for low calcium. Pixels were binned 2 × 2 to improve the
signal-to-noise ratio. The percent stuck filaments was estimated by
manually counting the gliding filaments within a randomly selected
area of each video. Filament speeds were determined by manually
tracking gliding filaments using the MTrackJ plug-in in ImageJ
(National Institutes of Health [NIH]). The speed at each calcium concentration was determined as the average of the speeds of n = 150
filaments from three independent experimental days (with 2–3 technical replicates per experimental day). For calcium concentrations
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that did not support continuous, directional filament gliding (pCa >
6.5 for WT, pCa > 5.75 for R134G), the speed was recorded as 0. The
pCa50, the calcium concentration that supported half-maximal
filament gliding speed, was determined by fitting a Hill equation to
the mean filament speed as a function of pCa. Statistical significance was assessed from the 95% confidence intervals of the fit
parameters (Altman and Bland, 2011).

Stopped-flow kinetic measurements of ADP release
Stopped-flow transient kinetic measurements were carried out in
buffer containing 60 mM MOPS, 200 mM KCl, 5 mM MgCl2, 1 mM
DTT, 2 mM EGTA, and 2.15 mM CaCl2 (pCa 4). Total concentrations
of calcium, magnesium, ATP, and EGTA added were calculated using
MaxChelator (Bers et al., 2010). Phalloidin-stabilized, pyrene-labeled
actin filaments were prepared by incubating 50 µM pyrene-actin with
55 µM phalloidin for at least 10 min at room temperature.
Fluorescent thin filaments (0.5 µM phalloidin-stabilized pyreneactin, 1 µM each troponin and tropomyosin) were preincubated with
myosin S1 (0.5 µM) and Mg·ADP (50 µM) and Mg·ATP (2.5 mM),
as previously described (De La Cruz and Ostap, 2009; Clippinger
et al., 2019). All concentrations refer to the final concentrations after
mixing. Release of ADP from the myosin active site (the rate-limiting
step) is followed by rapid binding of ATP, which results in myosin
dissociation from the thin filament and an exponential increase in
pyrene fluorescence. A single experiment consisted of recording at
least three kinetic time traces followed by fitting of a single exponential function to the averaged traces. The reported rate constant
(k) is the average of three (WT) or two (R134G) independent experiments, and reported errors are the propagated SEs from the fits.
Statistical significance was assessed using a Student’s two-tailed t
test executed in Excel (Microsoft).

Stopped-flow kinetic measurements of regulated
actomyosin binding
Stopped-flow transient kinetic measurements were carried out in
buffer containing 60 mM MOPS, pH 7.0, 200 mM KCl, 5 mM MgCl2,
1 mM DTT, 2 mM EGTA, and either 5.2 µM CaCl2 (pCa 9) or 2.15
mM CaCl2 (pCa 4). Total concentrations of calcium, magnesium,
ATP, and EGTA added were calculated using MaxChelator (Bers
et al., 2010). Phalloidin-stabilized, pyrene-labeled actin filaments
were prepared by incubating 50 µM pyrene-actin with 55 µM phalloidin in pCa 9 buffer at least 10 min at room temperature.
Fluorescent RTFs (2.5 µM phalloidin-stabilized pyrene-actin,
1 µM each troponin and tropomyosin) were rapidly mixed with
0.25 µM myosin S1 using an SX20 stopped-flow mixer (Applied
Photophysics). Apyrase VII (0.02 U/ml; Sigma) was included in each
protein solution to ensure the absence of nucleotide (i.e., ATP and
ADP). All concentrations are given as final concentrations after mixing. Pyrene was excited at 365 nm, and the fluorescence emission
was detected using a 395 nm cutoff filter. The fluorescence of the
pyrene-actin in the thin filaments was quenched by myosin strong
binding, yielding an exponential decrease in fluorescence. KB, the
equilibrium constant between the blocked and closed states of the
thin filament, was calculated by taking the ratio of the rate constants
of myosin binding at low (k [–Ca2+]; pCa 9) and high (k [+Ca2+]; pCa
4) calcium, as described by McKillop and Geeves (1993):
k ( −Ca 2+ )
k(

+Ca 2+

)

=

KB
1+ K B

(1)

A single experiment consisted of recording at least three kinetic
time traces at each calcium concentration followed by fitting of a
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single exponential function to the averaged traces. The reported KB
values are the average of 10 independent experiments, and reported errors are the SDs of these values. The statistical significance
between KB values was evaluated using a Student’s two-tailed t test
executed in Excel (Microsoft).

Fluorescence titrations of myosin binding to RTFs
Fluorescence titrations were performed at 20°C in buffer containing
60 mM MOPS, pH 7.0, 200 mM KCl, 5 mM MgCl2, 1 mM DTT, 2 mM
EGTA, and either 5.2 µM CaCl2 (pCa 9), 1.19 mM CaCl2 (pCa 6.25),
or 2.15 mM CaCl2 (pCa 4). Phalloidin-stabilized pyrene-actin was
prepared as described above. Measurements were performed using
a Fluoromax spectrophotometer (Horiba Scientific) equipped with a
TC 1 temperature controller (Quantum Northwest) and a Microlab
600 autotitrator (Hamilton). Myosin S1 was added to continuously
stirred RTFs (0.5 µM phalloidin-stabilized pyrene-actin and 0.27 µM
each troponin and tropomyosin) in the presence of 2 mM ADP, as
well as 50 µM P1,P5-di(adenosine-5′) pentaphosphate (Ap5a), 1 µM
hexokinase, and 2 mM glucose to maintain the nucleotide in the
ADP state, as described previously (McKillop and Geeves, 1993;
Barrick et al., 2019; Clippinger et al., 2019). S1 was added at 1-min
intervals in increments of 0.05 µM up to 0.2 µM, then at 0.2 µM increments up to 2 µM, and finally at 1 µM increments up to 10 µM.
The steady-state pyrene fluorescence was measured at 1-min intervals. Six technical replicates per condition were collected.
The fraction of myosin-bound subunits, f ([m]), is given by the
fractional change in pyrene fluorescence upon myosin binding,
which is related to parameters describing thin filament activation by
the following equation (McKillop and Geeves, 1993):
f ([m ]) =

F0 − F
F0 − F ∞

=

(

Kw [m ]P (nH −1) K T (1+ K S )

(nH )

)

+1


(nH ) + Q (nH ) + 1  (1+ K )(nH −1)
S
 K T P
K B 

(2)

where F is the measured pyrene fluorescence; F0 and F∞ are the
pyrene fluorescence in the absence of myosin and at saturating
myosin, respectively; [m] is the concentration of myosin; KW and
KS are the equilibrium constants for weak and strong myosin
binding, respectively; KB and KT are the equilibrium constants for
the described blocked-to-closed and closed-to-open transitions
of the thin filament, respectively; nH is the Hill coefficient for myosin binding to RTFs; P = 1 + [m]*KW(1 + KS); and Q = 1 + [m]*KW.
KB at pCa 9 was set to the value determined by stopped-flow kinetic measurements (see above). KB at high calcium and KS were
set to 20 and 18, respectively, based on McKillop and Geeves
(1993). The best-fit values and 95% confidence intervals for nH,
KW, and KT were determined by fitting Eq. 2 to the data using a
MATLAB-based computational tool (Barrick et al., 2019). The statistical significance of differences in these parameter values was
determined by bootstrapping, as previously described (Barrick
et al., 2019).

IAANS titrations
TnC carrying three mutations (C35S, T53C, C84S) was expressed,
purified, and labeled with 2-(4′-(iodoacetamido)anilino)napthalene6-sulfonic acid (IAANS; Toronto Research Chemicals) following published protocols (Davis et al., 2007; Clippinger et al., 2021). This
TnCT53C variant is fluorescently labeled by IAANS at its single cysteine residue. IAANS fluorescence is sensitive to the fluorophore environment, allowing IAANS-TnCT53C to report on the conformational
state of TnC. IAANS-TnCT53C was complexed with troponin I and
either WT or R134G troponin T as described above.
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IAANS titrations were carried out in buffer containing 10 mM
MOPS, 150 mM KCl, 3 mM MgCl2, and 1 mM DTT. Phalloidin-stabilized actin filaments were prepared by incubating 50 µM G-actin
with 55 µM phalloidin for at least 30 min at room temperature. Measurements were performed using the Fluoromax system described
above. Ca2+ was added to continuously stirred RTFs (2 µM phalloidin-stabilized actin, 0.45 µM tropomyosin, 0.15 µM troponin complex containing IAANS-TnCT53C) in the presence of 2 mM EGTA and
4.1 µM CaCl2 (pCa 9). Volumes of added calcium required to obtain
the desired final calcium concentrations were calculated using MaxChelator (Bers et al., 2010) and automatically added by the autotitrator. IAANS fluorescence was excited at 330 nm, and the emission
spectrum (370 to 550 nm) was recorded at 1-min intervals. Five technical replicates per condition were collected. The IAANS fluores-

cence was plotted against calcium concentration and fitted by a Hill
equation to determine the pCa50 as previously described (Davis
et al., 2007), with the modification that we analyzed the integrated
fluorescence from 530 to 550 nm. The statistical significance of the
difference in pCa50 for WT versus R134G was assessed by calculating a p value from the 95% confidence intervals of the fits (Altman
and Bland, 2011). Plots and fits were generated in MATLAB (MathWorks), and all other analysis was performed in Excel (Microsoft).

Preparation of human induced pluripotent stem
cell–derived cardiomyocytes
Parent and homozygous mutant induced pluripotent stem cells
were generated from the human BJ fibroblast line (CRL-2522; American Type Culture Collection) by the Genome Engineering and iPSC

FIGURE 8: Validation of gene-edited hiPSCs carrying the R134G mutation in troponin T. (A) Immunofluorescence
staining for pluripotency markers SSEA4, OCT4, SOX2, and TRA-1-61 in R134G hiPSCs. Cell nuclei are visualized using
4’,6-diamidino-2-phenylindole (DAPI) stain. (B) Karyotypes of R134G hiPSCs are normal.
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Center (GEiC, Washington University in St. Louis) with guide RNA
targeting TTCTCCTTAGGAGAGACGTCGGG and validated as previously described (Clippinger et al., 2019). We previously showed by
whole exome sequencing that the parent line has no known mutations associated with cardiomyopathy (Clippinger et al., 2019). Cell
identity was confirmed by the GEiC using short tandem repeat (STR)
sequencing. These cells had normal karyotypes (Cell Line Genetics;
Figure 8) and were tested for mycoplasma by the GEiC. Gene-edited cells were pluripotent, as determined by immunofluorescence
staining for SSEA4, OCT4, SOX2, and TRA-1-61 using the Pluripotent Stem Cell 4-Marker Immunocytochemistry kit (A25526; Thermo
Fisher) (Figure 8). Cells were cultured in feeder-free conditions as
previously described (Clippinger et al., 2019). These hiPSCs were
differentiated into cardiomyocytes (hiPSC-CMs) by temporal modulation of Wnt signaling as previously described (Lian et al., 2013;
Clippinger et al., 2019). hiPSC-CMs started spontaneously beating
7–10 d after the differentiation was initiated, and after metabolic
selection, >90% hiPSC-CMs were obtained, as previously described
(Clippinger et al., 2019). hiPSC-CMs were aged at least 30 d in culture before being used, and at least three differentiations were used
for the collection of all data sets.

Immunofluorescence imaging
(hiPSC-CMs were immunostained for α-actinin and troponin I (1:500
anti–α-actinin [A7811; Sigma]; 1:300 Cy2 anti-mouse [715225150;
Jackson ImmunoResearch]; 1:300 anti–troponin I [SC-15368; Santa
Cruz Biotechnology]; 1:300 Cy3 anti-rabbit [711165152; Jackson
ImmunoResearch]) and imaged using confocal microscopy, as previously described (Clippinger et al., 2019). Cell areas were calculated
from thresholded images in ImageJ (NIH). The sarcomere lengths
were calculated from the Fourier transform of the sarcomeric staining, as described in Pasqualini et al. (2015). Some data for WT
hiPSC-CMs were previously published in (Clippinger et al., 2019).
The statistical significance of differences was assessed using a MATLAB-based computational tool (Barrick et al., 2019).

Traction force microscopy
Traction force microscopy was performed as previously described
(Clippinger et al., 2019). Briefly, singularized hiPSC-CMs were
seeded onto rectangular Geltrex (Thermo Fisher) patterns
stamped onto 10 kPa hydrogels containing fluorescent marker
beads. The spontaneous beating of hiPSC-CMs was monitored using confocal microscopy. Traction force videos were analyzed using a MATLAB program developed by the Pruitt lab (Ribeiro et al.,
2017). Some data for WT hiPSC-CMs were previously published in
(Clippinger et al., 2019). The statistical significance of differences
in force generation was assessed using a MATLAB-based computational tool (Barrick et al., 2019).
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